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African horse sickness (AHS) is a non-contagious, insect-borne disease of equids caused by a RNA virus
(AHSV), which belongs to the genus Orbivirus, family Reoviridae. The disease is endemic in sub-Saharan
and western Africa, where prevention strictly depends upon vaccination. The present paper aims at
evaluating the serological response and the occurrence of AHS in horses bred under ﬁeld condition and
regularly immunized using the commercially available live attenuated vaccine (LAV) produced by
Onderstepoort Biological Products.
The study was carried out in a farm located in the district of Windhoek (Namibia), where the disease is
endemic. A total of 72 cross-breed horses, out of the 150 housed on the farm, were subdivided in six age
groups, from 2 to 7 years-old. Each group consisted of 12 heads which were born during the same breed-
ing season and had undergone from four to nine vaccination courses. AHSV speciﬁc immune response
was evaluated by serum-virus neutralization test. Data about the clinical occurrence of the AHS from
2006 to 2011 were made available. The immune response, in terms of number of seropositive horses
and serum neutralizing titers, was quite variable among horses and against different serotypes.
Neutralizing antibodies against all serotypes were recorded in all the horses only after eight vaccination
courses at 6 years of age onwards. Immune response to AHSV-5 and 9, which are not included in the LAV
formulation, were also established. A severe AHS epidemic occurred in Namibia in 2011. On the farm
under study, a total of 32 animals were clinically affected, 12 died, 11 of them were 2 year-old or younger.
Our data conﬁrm that vaccination with LAV is a useful tool to reduce the severity of the disease in ende-
mic areas. However, clinical and sometimes fatal AHS can still affect young vaccinated horses, thus high-
lighting the necessity to better understand the immune response to AHSV and to dispose of more
effective vaccines.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
African horse sickness (AHS) is a non-contagious insect-borne
disease of equids caused by a double stranded RNA virus (AHS
virus, AHSV) which belongs to the genus Orbivirus, family
Reoviridae, along with bluetongue and equine encephalosis viruses.
In naïve horse populations AHS is often fatal with a mortality rate
that may exceed 95%. High mortality rates may occasionally be
recorded also in mules, whereas infection is usually sub-clinical
or asymptomatic in African donkeys, differently from whatobserved in the European and Asiatic ones. Zebras rarely exhibit
clinical signs but play a relevant epidemiological role, thus being
regarded as the natural vertebrate reservoir of AHSV. However,
AHS is also endemic in African countries where zebra population
is absent or negligible as in Nigeria, indicating that other unknown
reservoir might exist [1,2].
AHSV genome consists of 10 RNA segments, which codify for 11
viral proteins. The structural protein VP2, located within the outer
capsid of the viral particle, represents the major neutralizing deter-
minant of the virus [3]. Up to date, nine AHSV serotypes (1–9) have
been identiﬁed by virus neutralization test. In vitro, some evidence
exists of serological cross-reactions among serotypes 6 and 9, 5 and
U. Molini et al. / Trials in Vaccinology 4 (2015) 24–28 258, 1 and 2, whereas no antigenic relationship has been demon-
strated with other known orbiviruses [1,2].
AHS is endemic in large areas of sub-Saharan Africa where all
serotypes are present. The disease has periodically occurred into
northern African countries, Iberian peninsula and Middle East up
to Turkey and India. AHSV-9 has been involved in the epidemics
in the Middle East (1959–63), Saudi Arabia, Yemen (1997), Cape
Verde Islands (1999), northern Africa and Spain (1966); in the lat-
ter country, a subsequent outbreak (1987), was caused by AHSV-4.
Such epidemics mainly resulted from the movement of infected
animals, although the spreading of infected vectors by wind, over
long distances, cannot be ruled out [2].
In Africa, biting midges Culicoides imicola and Culicoides bolitinos
are considered the most important vectors of AHSV. As a conse-
quence, AHS shows a typical seasonal occurrence, closely related
to rain and high environmental temperatures that favor breeding
of the vectors [1,2,4].
Colonization of different AHSV serotypes into western African
countries, from Nigeria to Mauritania, indicates that AHSV spread-
ing capacity is greater than previously thought [2,5].
In endemic areas, AHS prevention strictly depends upon
vaccination, that has undoubtedly provided protection from this
devastating disease. The use of a polyvalent vaccine seems manda-
tory in southern Africa, where all AHSV serotypes circulate with
different time distribution and prevalence [1,2,6,7]. A freeze-dried,
polyvalent live attenuated vaccine (LAV) produced by
Onderstepoort Biological Products (OBP) is currently used in south-
ern Africa. The vaccine is formulated in two components, which
have to be administered two or three weeks apart: (1) trivalent,
containing AHSV-1, 3 and 4; (2) tetravalent, containing AHSV-2,
6, 7 and 8. The OBP-LAV does not include AHSV-5, due to residual
virulence recorded in the ﬁeld in 1993 and AHSV-9, considered epi-
demiologically irrelevant in southern Africa. Furthermore, AHSV-6
should have provided some cross protection against AHSV-9, due
their serological cross-reaction. However, AHSV-5 and 9 both
dominated the 2006 AHS season, particularly in the Western
Cape Province [8].
It is widely accepted that several vaccination courses are
needed to immunize horses with OBP-LAV. According to the manu-
facturer, young horses should be treated at 6, 9 and 12 months of
age and thereafter yearly, before the AHS rainy season [8].
However, only few data exist about the immune response and
the efﬁcacy of OBP LAV under ﬁeld conditions [9,10].
On the basis of what above, the present study aimed at
investigating the serological response and the occurrence of AHS
in horses from 2 to 7 year-old, which had undergone from four to
nine vaccination courses with the OBP-LAV. Horses were housed
in a strictly controlled farm, supervised by a veterinarian, in the
Windhoek district (Namibia), where the disease is known to be
endemic. The investigation, implemented in collaboration with
the Namibian Ministry of Agriculture, Water and Forestry, was car-
ried out within the framework of the policy of preparedness of the
Italian National Reference Centre for Exotic Diseases (Istituto
Zooproﬁlattico Sperimentale dell’Abruzzo e Molise ‘‘G. Caporale’’,
Teramo, Italy).Materials and methods
Horses
The present study has been carried out on a farm located in the
district of Windhoek, approximately 82 km far from the Namibian
Capital. AHS is known to be endemic in Namibia, including the dis-
trict of Windhoek where different AHSV serotypes circulate [6,7].The farm housed 150 cross-breed horses, that number was kept
constant due to a speciﬁc replacement herd plan. All animals were
regularly vaccinated using the OBP-LAV. More in detail, young
horses were immunized at 6, 9 and 12 months of age, and then
annually re-vaccinated before the rainy season, between August
and October. No relevant side-effect to OBP-LAV was ever reported.
A total of 72 horses, out of the 150 were investigated. They were
selected in order to obtain six groups of 12 animals from 2 to
7 years of age. Younger animals, aged 6–12 months, were not avail-
able at the time of blood sampling, which was carried out in
November 2011, about 1 month after vaccination.
Serology
AHSV serotype-speciﬁc immune response was evaluated by
serum-virus neutralization test (SN) [11]. Details in Appendix A.
Outbreaks of AHS on the farm: Anamnestic data and laboratory tests
Clinical and pathological data about AHS outbreaks, which
occurred on that farm between 2006 and 2011, had been recorded
at the time and made available.
Blood samples in EDTA had been collected from live animals
during the febrile stage of infection, whereas dead horses had been
submitted to necropsy. Gross lesions had been systematically
recorded and several tissues (spleen, lung, cephalic, tracheo-bron-
chial and mediastinal lymph nodes) sampled for diagnostic
purposes.
Reverse transcriptase-polymerase chain reaction (RT-PCR) had
been ﬁrstly carried out to demonstrate or, alternatively, to rule
out the presence of AHSV; virus isolation and typing had been per-
formed according to previously described methods [12].
Statistical analysis
Probit analysis was applied to serological data. Nine probit
analysis, one for each serotype were performed [13,14]. Details in
Appendix A.Results
Serology
Serological results are summarized in Table 1. The immune
response, in terms of number of seropositive horses and SN titers,
were quite variable among horses and against the different AHSV
serotypes. In particular, at 2 years of age, after four vaccination
cycles, a high number of horses seroconverted against serotypes
6 and 7 whereas, at that time point, only a single horse showed
low immune response to AHSV-2. Antibody response in all horses
to all serotypes was recorded in the 6 and 7 year-old animal group
and varied between 1/10 and 1/640. Immune response to AHSV-5
and 9 were also recorded.
The probit analysis proved statistically signiﬁcant (v2 test p
value <0.001) and provided useful information about the timing
of serological immune response (Fig. 1). The probit model allowed
identifying a 95% conﬁdence interval (C.I.) of the time (i.e. age) dur-
ing which we can be conﬁdent to record a serological immune
response versus a speciﬁc AHSV serotype in 95% of horses. The low-
est values were obtained for AHSV-6 (C.I. 4.1–8.0 years) and AHSV-
1 (C.I. 4.8–8.7 years); on the contrary, the highest values were
found for serotypes 2 (C.I. 6.6–11.2 years) and 9 (C.I. 5.6–
12.9 years).
Table 1
Serotype-speciﬁc immune response in vaccinated horses of different age.
Age (years)/vaccination courses 2/4 3/5 4/6 5/7 6/8 7/9
AHSV serotypes Positive animals/total animals
1
SN titres Min–Max*
4/12
80–160
5/12
20–320
8/12
10–160
11/12
20–160
12/12
40–320
12/12
40–640
2
SN titres Min–Max*
1/12
10
1/12
10
1/12
20
4/12
10–160
12/12
10–160
12/12
10–640
3
SN titres Min–Max*
6/12
10–40
6/12
10–80
6/12
10–80
12/12
10–320
12/12
10–320
12/12
20–320
4
SN titres Min–Max*
5/12
10–320
6/12
40–640
7/12
10–640
10/12
20–160
12/12
10–640
12/12
80–640
5
SN titres Min–Max*
5/12
10–40
6/12
10–40
8/12
10–640
9/12
20–640
12/12
10–160
12/12
20–640
6
SN titres Min–Max*
8/12
10 – 160
8/12
10 – 160
8/12
10–80
12/12
10–160
12/12
10–320
12/12
40–640
7
SN titres Min–Max*
7/12
10–40
7/12
10–40
7/12
10–320
10/12
10–160
12/12
10–160
12/12
10–640
8
SN titres Min–Max*
4/12
10–80
4/12
10
7/12
10–640
9/12
10–640
12/12
10–640
12/12
10–640
9
SN titres Min–Max*
6/12
10–640
6/12
10–320
6/12
40–160
9/12
10–640
12/12
10–160
12/12
10–640
* Reciprocal of SN titres in horses immunized with OBP polyvalent live attenuated vaccine.
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Table 2 summarizes data about the occurrence of AHS from
2006 to 2011. No clinical case occurred in 2006 and 2007. In
2008, only two horses (2 and 4 years-old respectively), showed
mild AHS clinical signs, both recovered; AHSV 4 was isolated.
During the following 2 years, 2009–2010, no clinical case was
recorded. On the contrary, AHS showed a severe epidemic course
in 2011 concomitantly with heavy rain and ﬂooding. A total of
32 horses became clinically affected, with twelve fatal outcomes,
11 were 62 year-old or younger, one was aged 4 year.
The remaining recovering horses showed moderate fever (39.5–
40 C), subcutaneous edema at level of the supraorbital fossae, and
conjunctival petechiae. Fatal cases of AHS were clinically
characterized by prominent subcutaneous edema of head and
neck, conjunctival petechiae, permanent recumbency, severe dysp-
nea, and discharge of frothy ﬂuid from the nares.
At necropsy, the pulmonary form of AHS was observed in foals
aged 9–12 months old, while pathological changes of the pul-
monary and cardiac forms overlapped in the older ones.
Discussion
AHS is an extremely serious notiﬁable trans boundary infectious
disease affecting the respiratory and cardiovascular systems and
causing high mortality in horses, with a negative impact on the
equine industries of countries, such as South Africa and Namibia,
where the disease is endemic. Previous surveys demonstrated that
several AHSV serotypes (AHSV 1, 2, 4, 6, 7, 8 and 9) circulate in
Namibia. Under such circumstances, immunization with a polyva-
lent vaccine is considered the most, if not the only effective control
method [7,8].
Experimental studies demonstrated that serological response to
all AHSV serotypes is evident after the second OBP-LAV immuniza-
tion course and that the immune response is not enhanced in
horses given monovalent LAV, a ﬁnding that argues against the
antigenic competition among multiple AHSV serotypes. In addi-
tion, it has been recently shown that colostrum antibodies could
also inﬂuence timing of ﬁrst vaccination course [9,10,15].
In our studynodatawere available on the immune status of colts.
Interestingly, our results indicate that a higher number of OBP-LAVadministrations are required to reach a detectable serological
immune response under ﬁeld conditions. In accordance with von
Teichmanet al. [8], ourdata showthat the serotype-speciﬁc immune
response is quite variable amonghorses, aswell as against thediffer-
ent virus serotypes. Such ﬁndings might be due to a number of still
unknown host and/or vaccine related factors.
In vitro, serological cross-reactions have been demonstrated
between serotype 6 and serotype 9, as well as between serotype
5 and serotype 8. As also previously reported [8], such cross-reac-
tions could explain the detection of neutralizing antibodies against
the AHSV-5 and 9,wich are not included in the OBP-LAV. Actually,
the AHSV-9 speciﬁc immune response reported in the present
study might also result from natural and undetected infections,
since the serotype is known to circulate in the district of
Windhoek. On the contrary, that scenario seems questionable for
AHSV-5, the presence of which was not been reported in
Namibia during the years 2006–2011 [6,7].
As recently reported by Weyer [9], our data conﬁrm that immu-
nized horses can be affected by AHS. Although the LAV manufac-
turer relies on minimum protective SN titers of 1:16, the real
protective SN titer is still unknown and likely variable. In addition,
serum negative immunized horses could be also protected at chal-
lenge, a ﬁnding which might further remark the importance of the
cell-mediated immune response [9]. However, our data suggest
that seroconversion is an appropriate index of protection to clinical
disease. In fact, in the present study, clinical AHS affected horses
4 years old or younger and fatal outcomes almost exclusively
occurred in younger horses up to 2 years of age, which according
to the results shown could have been seronegative for some
AHSV serotypes. Remarkably, environmental conditions (heavy
rain) increasing the density of vectors and the viral load could be
regarded as additional factors, capable to affect the efﬁcacy of
the vaccine.
Taken together our data emphasize that the immune response
to AHSV is still poorly understood and that further studies are
needed to better clarify the interactions between the host’s
immune system, on one side, and the virus, on the other. OBP-
LAV still plays a crucial role in endemic areas, concerns still exist
about its safety, since attenuated virus recombination with wild
types AHSV might result in more virulent strains. As a conse-
quence, the prompt availability of effective inactivated and new
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Fig. 1. Serotype-speciﬁc probit analysis allows to determine a continuous 95% conﬁdence interval of the probability of achieving a positive result at any given input time
within the time range of the experiment. Upper and lower intervals expressed in years, for each seroptype, are shown.
Table 2
AHS cases recorded in the farm during the rainy seasons 2006–2011.
Year Age of AHS affected horses Number of AHS-affected
horses
Dead Recovered Vaccination
courses
AHSV serotype Annual rainfall
(mm)
Windhoek district
2006 // 0 // // // // Incomplete data
688
2007 // 0 // // // // Not available
2008 2 years 1 0 1 5 4 574
4 years 1 0 1 7 4
2009 // 0 // // // // 518
2010 // 0 // // // // 582
2011 6 months 4 4 0 1 4 (2 horses) and 6 (2 horses) 1221
9 months 3 3 0 2 4
1 year 5 2 3 3 4
2 years 12 2 10 4 6
3 years 2 0 2 5 n.d.
4 years 6 1 5 6 4
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28 U. Molini et al. / Trials in Vaccinology 4 (2015) 24–28generation vaccines appears highly desirable. Up to date, the latter
conﬁrmed to prevent AHS under experimental conditions, but have
not been pursued further [3,16–21].
Conclusions
In conclusion, our study indicate that the regular and correct
use of OBP-LAV is useful to reduce the severity of the disease.
However, the same results conﬁrm that vaccinated horses can be
affected by AHS under ﬁeld conditions, thus highlighting the
necessity to better understand the immune response, and to search
for alternative, more effective and safer vaccine.
Conﬂict of interest
None declared.
Appendix A
Serum–virus neutralization test
Collected sera were stored at 20 C and inactivated at 56 C for
30 min before testing. VERO cell (ECACC) at a concentration of
100,000 cells/ml were used. AHSV serotypes were made available
from the reference antigens, Bob Swanepoel collection. Sera were
diluted from 1:10 to 1:1280 and then incubated for 60 min with
100TCID50 of AHSV; the virus-serum mixtures were added in
duplicate to 92 well plates with conﬂuent cell monolayers. The
speciﬁc cytopathic effect was evaluated under a light microscope
after ﬁve days of incubation at 37 C in 5% CO2. Neutralizing titer
was deﬁned as the reciprocal of the highest dilution of serum, neu-
tralizing 100TCID50 of AHSV in P75% of the wells.
Statistical analysis
A model of non-linear regression (probit analysis) was applied
to serological data by means of a commercial software suite
(XLSTAT Version 2013.2.04 – Copyright Addinsoft, 1995–2013).
The qualitative response (positive or negative) was the depending
variable, while the time was the independent quantitative variable.
Probit analysis allows to determine a continuous 95% conﬁdence
interval of the probability to achieve a positive result at any given
input time, within the time range of the experiment. Nine probit
analyses, one for each serotype, were performed [13,14].
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